(Q44471523)

English

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors (English)
Patricia M LoRusso
Anne-Marie Maddox
Mace L Rothenberg
Andrea Feyereislova
Steven D Averbuch

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit